Skip to main content
. 2024 Oct 4;109(10):3157–3166. doi: 10.3324/haematol.2023.284409

Figure 3.

Figure 3.

Overall survival and event-free survival. Probabilities were estimated using the Kaplan-Meier method. Events were defined as non-response (not achieving complete remission [CR], CR with insufficient platelet recovery [CRi] or CR without recovery of counts [CRp], considered as event at day 0), relapse after remission achieved as a result of inotuzumab ozogamicin (InO) treatment, death from any cause, or secondary malignancies. Crosses represent censored subjects. Shaded areas represent the 95% confidence interval. OS: overall survival; EFS: event-free survival.